Insider Buying: Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Director Acquires 22,686 Shares of Stock
by Renee Jackson · The Cerbat GemSenseonics Holdings, Inc. Common Stock (NASDAQ:SENS – Get Free Report) Director Douglas Roeder purchased 22,686 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was purchased at an average price of $5.56 per share, for a total transaction of $126,134.16. Following the completion of the transaction, the director directly owned 144,635 shares in the company, valued at $804,170.60. This trade represents a 18.60% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link.
Senseonics Holdings, Inc. Common Stock Trading Down 4.5%
Shares of NASDAQ:SENS traded down $0.26 during mid-day trading on Wednesday, reaching $5.50. The stock had a trading volume of 563,767 shares, compared to its average volume of 637,784. The company has a market cap of $229.90 million, a price-to-earnings ratio of -2.75 and a beta of 1.05. The stock has a 50 day moving average of $6.47. The company has a debt-to-equity ratio of 1.05, a quick ratio of 4.55 and a current ratio of 3.51. Senseonics Holdings, Inc. Common Stock has a twelve month low of $4.79 and a twelve month high of $12.58.
Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.06). Senseonics Holdings, Inc. Common Stock had a negative net margin of 213.87% and a negative return on equity of 129.97%. The business had revenue of $11.71 million for the quarter. On average, equities analysts anticipate that Senseonics Holdings, Inc. Common Stock will post -2.7 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the company. Stifel Nicolaus cut their price objective on Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating on the stock in a report on Monday. HC Wainwright cut their price objective on Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Weiss Ratings assumed coverage on Senseonics Holdings, Inc. Common Stock in a report on Tuesday, February 17th. They set a “sell (d-)” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $17.00.
View Our Latest Stock Report on Senseonics Holdings, Inc. Common Stock
Institutional Investors Weigh In On Senseonics Holdings, Inc. Common Stock
Several institutional investors have recently bought and sold shares of SENS. Ausdal Financial Partners Inc. lifted its stake in Senseonics Holdings, Inc. Common Stock by 50.0% in the 3rd quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock valued at $46,000 after acquiring an additional 35,000 shares in the last quarter. Townsend Asset Management Corp NC ADV bought a new stake in Senseonics Holdings, Inc. Common Stock in the 4th quarter valued at approximately $60,000. GSK plc bought a new stake in Senseonics Holdings, Inc. Common Stock in the 4th quarter valued at approximately $60,000. Kestra Advisory Services LLC bought a new stake in Senseonics Holdings, Inc. Common Stock in the 1st quarter valued at approximately $68,000. Finally, Sanctuary Advisors LLC bought a new stake in Senseonics Holdings, Inc. Common Stock in the 4th quarter valued at approximately $71,000. Institutional investors own 12.36% of the company’s stock.
Senseonics Holdings, Inc. Common Stock Company Profile
Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.
Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.